Bronchogen calculator
A short 'peptide bioregulator' from the Russian cytomedin tradition, marketed for respiratory support. Evidence is thin and largely non-Western.
Also known as: Bronchial peptide bioregulator
FDA status — not an approved drug Not FDA-approved for any use. Bronchogen is a peptide bioregulator sold as a research or supplement product and is not reviewed by FDA.
Schedule Bronchogen → Set your dosing schedule and get a phone notification when each dose is due. Free.
What Bronchogen is
Bronchogen is a short peptide marketed as a 'bioregulator' for the bronchial and respiratory system. It belongs to the cytomedin class developed in Russia, which claims organ-specific normalizing effects. It is not approved in the United States and has minimal presence in the international trial literature.
Research depth: 1/5 Limited regional research; no large randomized or Western trials. Human trials: None published in major journals. This measures how much has been studied — counting animal and laboratory work — not whether it works for you.
How Bronchogen works
Proponents claim short peptides enter cells and modulate gene expression in a tissue-specific way, restoring function in the organ from which the peptide class was derived. This mechanism is not established by rigorous, reproducible research, and independent validation is lacking.
Bronchogen side effects
Commonly reported
- Generally reported as well tolerated in regional literature
- No robust Western safety data
Serious — seek medical care
- Evidence base is thin and not independently replicated
- Quality and purity vary widely among suppliers
- Not a substitute for evidence-based respiratory care
This list is not exhaustive. Report anything unexpected to the clinician who prescribed it. If you have severe abdominal pain, trouble breathing, or signs of an allergic reaction, seek care the same day. See also our guide to peptide side effects by class.
A worked example
A 20 mg vial reconstituted with 1 mL of bacteriostatic water gives 20 mg/mL. A 20000 mcg dose is then 1 mL — about 100 units on a 100-unit insulin syringe, giving roughly 1 doses per vial before accounting for residual volume left in the vial and syringe.
Prefer paper? Download the printable Bronchogen dosing chart (PDF) — every vial size and water volume in syringe units, with the same review byline as this page. All charts →
Commonly cited dose range
Figures circulating for Bronchogen run from 10000 mcg to 30000 mcg. Bioregulator peptides are typically sold as oral capsules dosed in milligrams. Figures shown are community reference amounts in micrograms. There is no established or approved dose.
Read this as reference information, not instruction. These numbers describe what is commonly discussed, not what is right for any individual. Dose, frequency, and whether to use Bronchogen at all are decisions for a licensed clinician who knows your history.
Common questions
What is a peptide bioregulator?
A class of short peptides (often di- to tetra-peptides) developed mainly in Russia, claimed to normalize the function of specific organs. The claims rest largely on regional research that has not been reproduced in large Western trials.
Is Bronchogen proven to help the lungs?
No robust Western clinical evidence supports it. It is a regional product with limited, mostly non-randomized data.